following a full submission:
ixekizumab (Taltz®) is accepted for restricted use within NHS Scotland.
Indication under review: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.
Ixekizumab was superior to placebo and to a tumour necrosis factor (TNF) antagonist for improving symptoms of adults with moderate to severe plaque psoriasis.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ixekizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
|Drug Name:||ixekizumab (Taltz)|
|SMC Drug ID:||1223/17|
|Manufacturer:||Eli Lilly and Company Ltd|
|Indication:||Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.|
|Sub Category:||13.5 Preparations for eczema and psoriasis|
|Submission Type:||Full submission|
|Date Advice Published:||10 April 2017|